Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

IntraVenous Immune Boost

Objetivo

What if we could finally treat metastatic patients and uncurable cancers like sarcomas ?
HEPHAISTOS-Pharma developed ONCO-Boost, the first-in-class intravenous TLR4 immunostimulant that will be a game changer in immunotherapy. This innovation was discovered after 40 years of research from a woman entrepreneur who developed a mature, scalable, disruptive and eco-friendly platform. ONCO-Boost can cure hard to treat cancers as a stand-alone treatment but can also increase the efficacy of existing treatments. Our cure is injected intravenously and this changes everything, we can offer therapeutic options for patients with metastatic cancers and hardly accessible tumors. As such, ONCO-Boost can cure 10x more patients than competitors, all limited to intratumoral injection. HEPHAISTOS' ambition is to become the European leader in immunostimulants, with a platform able to supply the market with large quantities of drugs, able to save millions of patients each year.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-EIC-2023-ACCELERATOR-01

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

HEPHAISTOS-PHARMA
Aportación neta de la UEn
€ 2 249 749,00
Dirección
21 RUE JEAN ROSTAND
91400 Orsay
Francia
Pyme
Sí
Región
Ile-de-France Ile-de-France Essonne
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 6 910 955,50

Participantes (1)